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Adenosine is a nucleoside mainly formed by degradation of ATP, located intracellularly
or extracellularly, and acts as a neuromodulator. It operates as a volume transmission
signal through diffusion and flow in the extracellular space to modulate the activity of
both glial cells and neurons. The effects of adenosine are mediated via four adenosine
receptor subtypes: A1R, A2AR, A2BR, A3R. The A2AR has a wide-spread distribution
but it is especially enriched in the ventral and dorsal striatum where it is mainly
located in the striato-pallidal GABA neurons at a synaptic and extrasynaptic location.
A number of A2AR heteroreceptor complexes exist in the striatum. The existence
of A2AR-D2R heteroreceptor complexes with antagonistic A2AR-D2R interactions
in the striato-pallidal GABA neurons is well-known with A2AR activation inhibiting
Gi/o mediated signaling of D2Rs. A2AR-mGluR5 heteroreceptor complexes were also
found in with synergistic receptor-receptor interactions enhancing the inhibition of
the D2R protomer signaling. They are located mainly in extrasynaptic regions of the
striato-pallidal GABA neurons. Results recently demonstrated the existence of brain
A2AR-A2BR heteroreceptor complexes, in which A2BR protomer constitutively inhibited
the function of the A2AR protomer. These adenosine A2AR heteroreceptor complexes
may modulate alpha-synuclein aggregation and toxicity through postulated bidirectional
direct interactions leading to marked increases in A2AR signaling both in nerve cells and
microglia. It is of high interest that formation of A2AR-A2ABR heteroreceptor complexes
provides a brake on A2AR recognition and signaling opening up a novel strategy for
treatment of A2AR mediated neurodegeneration.
Keywords: G protein-coupled receptor, neurodegeneration, adenosine A2A receptor, heteroreceptor complexes,
oligomerization, adenosine receptor, Parkinson’s diseases, neuroinflammation
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INTRODUCTION
Adenosine is a nucleoside mainly formed by degradation of
ATP located intracellularly or extracellularly and acts as a
neuromodulator (Fredholm, 1995; Gomes et al., 2011). In the
extracellular fluid of the neuronal-glial networks of the Central
Nervous System (CNS), it operates as a volume transmission
signal through diffusion and flow to modulate the activity of
both glial cells and neurons (Fuxe et al., 2010). It also acts
as a homeostatic modulator (Gomes et al., 2011). Intracellular
adenosine can reach the extracellular space through inter alia
equilibrative transporters in the plasma membrane. The effects
of adenosine are mediated via four adenosine receptor subtypes:
A1R, A2AR, A2BR, A3R (Fredholm, 1995; Fredholm et al., 2011).
The A1R is distributed all over the CNS and found in high
densities. It is coupled to Gi/o and inter alia inhibits adenylyl
cyclase (AC) and calcium channels, and activates potassium
channels. Being located both in synaptic and extrasynaptic
positions at the pre and postsynaptic level, it inhibits synaptic
transmission and hyperpolarizes nerve cells (Gomes et al., 2011).
The A1R is also expressed in astroglia and microglia to fine tune
neuronal-glial interactions.
The A2AR has a wide-spread distribution but it is especially
enriched in the ventral and dorsal striatum where it is mainly
located in the striato-pallidal GABA neurons at a synaptic and
extrasynaptic location (Fuxe et al., 2003; Gomes et al., 2011;
Brugarolas et al., 2014; Navarro et al., 2016a). It is coupled
to Gs/olf proteins, activates AC, enhances glutamate release
and enhances the activity of the striato-pallidal GABA neurons
involving also inhibition of their inhibitory dopamine D2R
located at the postsynaptic level (Fuxe et al., 2007; Gomes et al.,
2011).
Unlike the A2AR the A2BR is coupled Gs/q, which leads
to PLC activation and increases in intracellular calcium levels
(Linden et al., 1999; Fredholm et al., 2011; Goncalves et al., 2015).
The A2BR has been scarcely studied in the CNS. A difference
from A1R and A2AR is that they are activated by adenosine
only at micromolar adenosine concentrations, whichmay be only
reached in pathological states (Müller and Stein, 1996). Their
physiological role remains unclear but highly interesting results
were recently obtained demonstrating the existence of A2AR-
A2BR heteroreceptor complexes, in which A2BR protomer
constitutively inhibited the function of the A2AR protomer (Hinz
et al., 2017, in press).
With regard to the A3R it was shown to be located in neurons
of the hippocampus based on the presence of A3R mRNA levels
in hippocampal neurons using single cell PCR analysis (Lopes
et al., 2003). The A3R possesses a high affinity for adenosine and
is mainly coupled to Gi2.3. It therefore inhibits AC signaling but it
can also activate PLC (Fredholm et al., 2011). Activation of A3Rs
found in hippocampal nerve terminal membranes usingWestern
blot analysis, produces neuroprotective actions (Boison, 2010;
Boison and Shen, 2010; Fishman et al., 2012). It is of high interest
that A3R activation selectively brings down persistent pain states
through its analgesic properties (Little et al., 2015).
In the current perspective paper we will give an update
of the adenosine A2AR heteroreceptor complexes that may
be expressed in the CNS and to which extent they may
participate and help explain molecular mechanisms underlying
the involvement of adenosine receptors in neurodegeneration
and neuroinflammation.
ADENOSINE A2ARS MODULATE
ALPHA-SYNUCLEIN AGGREGATION AND
TOXICITY. POSSIBLE INVOLVEMENT OF
A2AR HETERORECEPTOR COMPLEXES
Adenosine A2A Receptor-Alpha-Synuclein
Interactions
Alpha-synuclein mediated excitotoxicity involves increased
calcium flow over the NMDA channels (Diogenes et al., 2012).
In an exciting paper Ferreira et al. (2017a) demonstrated that
A2AR antagonists and A2AR genetic deletion counteracted
cell death produced by alpha-synuclein. The number of cells
forming inclusions of alpha-synuclein was also reduced but not
oligomerization of alpha-synuclein. In contrast, A2AR activation
enhanced calcium flow over the NMDA channels (Rebola et al.,
2008) as found after alpha-synuclein. Furthermore, the toxic
effects of alpha-synuclein on long term depression (LTD) were
abolished by reducing A2AR activity. It is of high interest that this
rescue of synaptic function was dependent on NMDA receptor
signaling (Ferreira et al., 2017a,b). In line with these results it
was suggested that activation of A2ARs can produce a substantial
increase of activity in synaptic NMDA receptor function
causing excitotoxicity (Besancon et al., 2008). Aberrant A2A
receptor signaling demonstrated in synucleinopathy participates
in reductions of cognition and neurodegeneration (Hu et al.,
2016).
The detailed mechanisms on how alpha-synuclein
accumulation produces a marked increase of A2AR signaling
leading to toxicity remain to be clarified but may involve
increases in extracellular adenosine levels (Ferreira et al., 2017a)
enhancing adenosine volume transmission events. It is proposed
that alpha-synuclein monomers, especially in an alpha helix
conformation, may bind to domains of the A2AR producing an
enhanced Gs/olf coupling and/or modulation of A2A protomers
in heteroreceptor complexes (Figures 1, 2). This proposal is
based on the fact that GPCRs can bind to a number of proteins to
form homo and heteroreceptor complexes (Bockaert et al., 2010;
Fagni, 2012; Borroto-Escuela et al., 2016a). As a consequence
PKA activity linked to the A2AR would be enhanced. It was
in fact demonstrated that alpha-synuclein phosphorylation at
serine 129 was associated with formation of Lewy bodies and
neurodegeneration of DA neurons (Fujiwara et al., 2002). In
line with these results A2AR antagonists can also reduce Tau
hyperphosphorylation linked to memory improvement (Laurent
et al., 2016). Such a scenario can help explain the neuroprotective
actions of A2AR antagonists involving their ability to counteract
the alpha-synuclein aggregation (Ferreira et al., 2017a). It also
seems possible that the increased A2AR activation can bring
down the activity of alpha-synuclein induced clearance via
autophagy involving reduced lysosomal function (Decressac
et al., 2013). Such events blocked by A2AR antagonists may
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FIGURE 1 | Illustration of the adenosine heteroreceptor complexes found in the GPCR heteroreceptor network (GPCR-hetnet; left large panel) and the synaptic and
extrasynaptic regions of the glutamate synapse in the striato-pallidal GABA neurons (right panel). Also PLA positive red clusters of A1R-A2AR and A2AR-A3R
isoreceptor complexes in the CA1 pyramidal cell layer (lower right panel) are shown (Lower right panels). In the GPCR-hetnet the adenosine isoreceptor complexes are
highlighted in blue and adenosine heteroreceptor complexes in yellow. In the extrasynaptic regions the A1R-A2AR isoeceptor complex is shown in the glutamate nerve
terminal and the A2AR-D2R and A2AR-mGluR5 at the postjunctional level. At the postsynaptic level the putative A2AR-mGluR5-NMDAR and A2A-D2R-NMDAR
complexes are indicated together with A2AR-FGFR1. It seems likely that most heteroreceptor complexes can have both a synaptic and extrasynaptic position.
lead to rescue of cells from alpha synuclein toxicity. Thus, the
autophagy-lysosome pathway comes into focus.
In line with the view above, it was recently established that
aberrant A2AR signaling can contribute to neurodegeneration
and cognitive deficits in a model of synucleinopathy (Hu et al.,
2016). Interestingly, A2AR deletion results in neuroprotection
in a mouse model of tauopathy (Laurent et al., 2016).
Neuroprotection was associated with reductions of Tau
hyperphosphorylation and markers of neuroinflammation and
counteractions of memory deficits. A2AR antagonists produced
protective actions. Similar molecular mechanisms may be
involved in the A2AR triggered molecular pathology as discussed
above for alpha-synuclein. Indications were also found that
GSK-3β, a serine-threonine kinase, and BDNF can participate
in these events (Laurent et al., 2016). Taken together, these
seminal papers make it clear that A2AR should become targets
for treatment of alpha-synucleinopathies and Tauopathies.
A2AR Heteroreceptor Complexes
Putative A2AR-D2R-NMDAR Heteroreceptor
Complexes
The existence of A2AR-D2R heteroreceptor complexes with
antagonistic A2AR-D2R interactions is well-known with A2AR
activation inhibiting Gi/o mediated signaling of D2Rs (Hillion
et al., 2002; Canals et al., 2003; Navarro et al., 2009, 2010;
Borroto-Escuela et al., 2010a,b, 2013b; Figures 1, 2). They are
highly expressed in the striato-pallidal GABA neurons in synaptic
and extrasynaptic location related to glutamate synapses (Fuxe
et al., 2005, 2010, 2014c,d). In these neurons also D2R-NMDAR
heteroreceptor complexes exist in glutamatergic synapses with
D2R activation leading to inhibition of NMDAR signaling (Liu
et al., 2006). The interface involves the C-terminal part of the
subunit GluN2B of the NMDAR and the intracellular loop 3 of
the D2R. D2R activation interferes with the ability of CaMKII to
bind to GluNR2B and therefore reduces the phosphorylation of
this subunit leading to a reduction of the NMDAR currents (Liu
et al., 2006).
Based on these results it seems possible that striatal
A2AR-D2R-NMDAR heteroreceptor complexes may exist,
in the striato-pallidal GABA neurons in a synaptic and/or
extrasynaptic position, and in cortical regions but in
lower densities than in the striatum. It may therefore
be considered that alpha-synuclein induced altering of
A2AR signaling can produce neuronal cell death through
allosteric inhibition of D2R function which disinhibits
NMDAR signaling in this heteroreceptor complex. As a
result calcium influx is increased and excitotoxicity may
develop.
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FIGURE 2 | Illustration of possible molecular mechanism by which alpha-synuclein monomers/oligomers/ synuclein fibrils can modulate the homo-heteroreceptor
complexes balance and panorama in the plasma membrane. In the far left part of the figure it is indicated that monomeric alpha-synuclein transmembrane (TM)
peptide can become linked to A2AR homoreceptor complex and modulate the A2AR function. The A2AR antagonist may then favor the formation of non-propagating
synuclein dimers (pathway highlighted in red). The A2A receptor agonist induced A2AR activation (pathway highlighted in green) may instead favor the propagation of
the synuclein dimers/oligomers into small and large synuclein aggregates leading to formation of Lewy bodies. Ring-like synuclein oligomers may also be formed
which may enter the membrane and there produce beta sheet structures that associate and give rise to pores in the plasma membrane through which calcium ions
may pass. In the A2AR-mGluR5 heteroreceptor complex the signaling pathways are illustrated and how protein kinases like PKA, PKC and calcium-calmodulin kinase
II activities can have a role in the modulation of the synuclein aggregation process. The A2AR-D2R-NMDAR complex, to which the alpha-synuclein monomer may
bind to the A2AR, is also illustrated to indicate that A2AR activation can mediate toxicity also by turning on NMDAR signaling via inhibition of the D2R induced
allosteric antagonistic interaction with the NMDAR. In this way the calcium influx through these ion channels is reduced as well as its coupling to nitric oxide (NO)
toxicity. It is also indicated that beta sheet rich intermediates of alpha-synuclein peptides may bind to the intracellular loops and C-terminal of the receptor protomers
of this heteroreceptor complex and modulate their signaling. They may also disturb the signaling of the G proteins and beta-arrestin. Finally to the far right the
A2AR-FGFR1 heteroreceptor complex is presented with the alpha-synclein monomer bound to the A2AR. The role of this receptor complex in the degeneration
process is unknown but FGFR1 activation by the A2AR may enhance structural plasticity and reduce toxicity.
It is known that calcium transients in spines can impact
various signal transduction cascades leading inter alia to effects
on cell survival and apoptosis, which are context dependent
(Kennedy et al., 2005). It is of high interest that the C-terminal
of the GluN2B subunit can be linked to the post-synaptic density
95 (PSD-95) protein via the PDZ domain (Kornau et al., 1995;
Cui et al., 2007). Through this connection the activated NMDAR
can become linked to nitric oxide neurotoxicity (Sattler et al.,
1999). By counteracting this interaction through knockdown of
PSD-95, calcium-activated nitric oxide production is blocked.
The hypothesis of this trimeric heteroreceptor complex deserves
to be tested in cellular models.
Putative A2AR-mGluR5-NMDAR Heteroreceptor
Complexes
A2AR-mGluR5 heteroreceptor complexes were found in the
striatum with synergistic receptor-receptor interactions located
mainly in extrasynaptic regions (Ferre et al., 2002; Rodrigues
et al., 2005; Tebano et al., 2005; Cabello et al., 2009; Borroto-
Escuela et al., 2016a; Figure 1). Direct interactions were
found between NMDAR and mGluR5 and reciprocal allosteric
receptor-receptor interactions exist between them (Perroy et al.,
2008). In neurons both synergistic and antagonistic receptor-
receptor interactions can be observed between NMDAR and
mGluR5 (Perroy et al., 2008). One explanation can be the
dynamic association of the scaffolding proteins Homer-Shank to
themGluR5-NMDARheteroreceptor complex (Husi et al., 2000).
As examples can be mentioned that the D2 receptor can form a
protein complex with Disrupted in Schizophrenia 1 (DISC1; Su
et al., 2014) and with the sigma1 receptor (Borroto-Escuela et al.,
2016b, 2017) altering its signaling and recognition in a dynamic
way. Cocaine targets the sigma1 receptor with high affinity and
modulates allosteric D2R-sigma1R receptor-receptor interactions
on dopamine and glutamate nerve terminals from rat striatum
(Beggiato et al., 2017). D2R-sigma1R-DAT complexes also appear
to exist in the DA nerve terminals, in which cocaine in nanomolar
concentrations increases D2R signaling.
In view of these findings there is the possibility that A2AR
can increase NMDAR signaling also via allosteric enhancement
of mGluR5 function. In this case, however, there is an allosteric
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enhancing action of NMDAR signaling produced by mGluR5.
This proposal can be tested in neuronal cell cultures.
GLIAL A2ARs AND
NEUROINFLAMMATION. POSSIBLE ROLE
OF A2AR HETERORECEPTOR
COMPLEXES
Microglia
It is important to underline that also adenosine A2ARs expressed
in microglia can be involved in the neurodegenerative processes
brought about by increased A2AR-mediated transmission. It is
of high interest to note that one pathologic event is sufficient to
induce a gain-of-function of microglial A2AR signaling via Gs-
AC-PKA pathways but not of microglial adenosine A1R, A2BR,
and A3R signaling (Santiago et al., 2014). This process involves
enhancement of neuroinflammation through inter alia A2AR-
induced expression and release of multiple proinflammaory
cytokines like IL-1beta, IFN-gamma, and TNF from microglia
(Santiago et al., 2014).
Through extracellular vesicle mediated volume transmission,
proteins like receptors, and alpha-synuclein can be transferred
from cell to cell via inter alia exosomes diffusing in the
extracellular fluid to be incorporated into other cells through
vesicular endocytosis (Agnati et al., 2010, 2014; Angot et al.,
2012; Agnati and Fuxe, 2014; Borroto-Escuela et al., 2015;
Dehay et al., 2016). This cell to cell transfer process of
alpha-synuclein can explain the spread of alpha-synuclein
induced neurodegeneration in the CNS and can involve both
nerve cells, astroglia, and microglia (Borroto-Escuela et al.,
2015; Fuxe and Borroto-Escuela, 2016). It seems possible that
transfer of alpha-synuclein to microglia can be involved in the
upregulation of microglial A2AR, which contributes to increased
neuroinflammation.
The putative existence of A2AR isoreceptor complexes and
their function in the microglia remains to be clarified. However,
it has been shown that a receptor heteromer mediated regulation
of endocannabinoid signaling exists in activated microglia. It is
also of substantial interest that A2AR-CB1R-D2R heteroreceptor
complexes were demonstrated in living cells using the sequential
BRET-FRET technique (Carriba et al., 2008). Thus, A2AR-
CB1R heteroreceptor complexes may exist in basal and/or
activated microglia. There is an upregulation of CB1R-CB2R
heteromers in activated microglia which is of relevance for
Alzheimer’s disease and levodopa-induced dyskinesia (Navarro
et al., 2017). Dyskinesia in Parkinson’s was found to correlate with
CB1R-CB2R heteroreceptor complex upregulation in activated
microglia. However, we also propose that the disbalance of
activity in the direct and indirect pathways due to pathological
alterations in the D1R and D2R heteroreceptor complexes in
these two pathways can be a significant cause of dyskinesia
development. Thus, e.g., the initiation ofmovements by the direct
pathway may not be appropriately associated with a balanced
reduction of motor inhibition of the indirect pathway. This may
results in an exaggerated removal of motor inhibition which can
lead to dyskinesia development upon treatment with L-DOPA.
It remains to be tested if also A2AR heteroreceptor complexes
may participate in mediating proliferation and enhanced
reactivity of upregulated microglia and have an impact on
neuroinflammation and neurodegeneration. It is known that in
neuroinflammation adenosine A2ARs can mediate microglial
process retraction giving the microglia their ameboid appearance
under these conditions (Orr et al., 2009). However, in another
state of neuroinflammation A2AR activation can also trigger
proliferation of microglia through microglial release of BDNF
(Gomes et al., 2013) and/or nitric oxide release (Saura et al.,
2005). Thus, the signaling consequences of A2AR activation in
microglia may vary depending on the type of inflammatory state
present in the microglia. Each state may be associated with
the dynamic formation of special types of A2AR isoreceptor
complexes dependent on the inflammatory state induced.
Astroglia
Central dopamine and noradrenaline neurons communicate with
astroglia via volume transmission and the existence of astroglial
dopamine D1R and D2R receptors (Fuxe et al., 2015). The
astroglial perivascular endfeet have an important role in the
clearance of waste products via the Glymphatic system where G
stands for glia (Iliff et al., 2013; Jessen et al., 2015). This function
is related to their expression of a high density of aquaporin-4
(Aqp4) water channels reducing the resistance to water flow. It
was proposed that GPCRs like A2AR and D2R can modulate
the water influx and outflux over the Aqp4 channels (Fuxe
et al., 2015) present in the plasma membrane of astroglia, via
direct receptor-water channel interactions involving allosteric
mechanisms.
Recently it was possible to demonstrate in astrocytes from
adult striatum that D2R and A2AR receptors coexist in the
same astrocyte process using confocal microscopy (Cervetto
et al., 2017). Furthermore, A2AR activation was found to
inhibit the D2R induced inhibition of astroglial glutamate release
elicited by 4-aminopyridine (Cervetto et al., 2017). By itself
the A2AR agonist lacked effects on the glutamate release from
astroglia. This action suggests a receptor-receptor interaction
in astroglial A2AR-D2R heteroreceptor complexes since it was
blocked by a D2R synthetic peptide interfering with A2AR-D2R
heteromerization (Cervetto et al., 2017). It seems possible that
this receptor complex also can directly interact with the astroglial
Aqp4 water channels.
Overactivity of astroglial A2AR would thus enhance astroglial
glutamate release since there will be a brake on inhibitory
astroglial D2R signaling via the A2AR protomer. The impact on
synaptic glutamate transmission of increased astroglial glutamate
release is difficult to foresee. Extrasynaptic mGluR should be
mainly reached. If the major receptor activation by astroglial
glutamate involves the inhibitory mGluR2-4, coupled to Gi/o
and located on the glutamate nerve terminals, a reduction of
neuronal glutamate release would take place with inhibition
of glutamate transmission and reduction of the activity of the
striato-pallidal GABA neurons (Kalivas, 2009; Kalivas et al.,
2009). Thus, reduced toxicity will occur. However, if also
extrasynaptic and postsynaptic mGluR1 and mGluR5 coupled
to Gq are substantially activated by astroglial glutamate release,
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glutamate synaptic strength can be increased. This can involve
increases in intracellular calcium levels and increased inhibition
of D2R signaling in A2AR-D2R-mGlu5R complexes (Cabello
et al., 2009), where A2AR and mGluR5 protomers synergize to
inhibit D2R signaling mediated via Gi/o. Under such scenario,
glutamate toxicity is not expected to change unless extrasynaptic
NMDAR/AMPAR/ kainate receptors become critically activated
by astroglial glutamate.
The astroglial glutamate transporter-1 is also of relevance
for excitotoxicity. The mechanism involves Na/K-ATPase-
alpha2 coupled to the astroglial glutamate transporter. It is
of high interest that the A2AR can directly bind to the
astroglial Na/K-ATPase-alpha2 as indicated using proximity
ligation assay and co-immunoprecipitation (Matos et al., 2013).
Furthermore, activation of the A2AR inhibits the astroglial
glutamate uptake through inhibition of Na/K-ATPase-alpha2
activity. This antagonistic interaction involving the above
described receptor-protein complexes can further increase the
extracellular glutamate levels that may reach a critical level
to produce excitotoxicity. Through this mechanism involving
A2AR activation ion homeostasis as well as the astrocyte-
neuron lactate shuttle requiring astroglial glutamate uptake can
deteriorate (Pellerin et al., 1998). The shuttle means that there is
a transfer of lactate from astrocytes to neurons. Thus, astrocytes
serve as a source of lactate and neurons as a sink for lactate. In
this way lactate can help glucose support oxidative metabolism
in neurons made possible through astroglial processes (Pellerin
et al., 1998).
FORMATION OF A2AR-A2BR
HETERORECEPTOR COMPLEXES
PROVIDES A BRAKE ON A2AR
RECOGNITION AND SIGNALING
It was recently found that the two isoreceptors A2AR and A2BR
can form heteroreceptor complexes in living cells and in brain
tissue using BRET, FRET, BiFC, and proximity ligation assay
(PLA) techniques (Hinz et al., 2017, in press). Remarkably, the
demonstration that the A2AR protomer within A2AR-A2BR
heteroreceptor complex loses its high affinity binding coupled to
marked reduction of the potency of A2AR agonists to activate
the Gs-AC pathway with accumulation of cAMP (Hinz et al.,
2017, in press). The A2BR is an adenosine receptor with a low
affinity for adenosine in contrast to the A2AR with high affinity
for adenosine. So far the A2AR-A2BR heterocomplexes have been
found in the cerebral cortex and in the hippocampal cortex by
using PLA (Hinz et al., 2017, in press).
Based on these exciting findings it seems possible that
an upregulation of A2BR expression in the glial-neuronal
networks of the brain, which have been reported in
neuroinflammation (Feoktistov and Biaggioni, 2011), can
block the neurodegenerative effects by A2AR inactivation. Such
an upregulation may increase the formation of A2AR-A2BR
heteroreceptor complexes which should markedly reduce the
A2AR-mediated signaling. These events can take place when
the two adenosine receptors are expressed in the same nerve
or glial cells. However, it should be considered that through
extracellular vesicle (ECV) mediated volume transmission
(Guescini et al., 2012; Borroto-Escuela et al., 2015), A2BRs can be
transferred to cells expressing A2AR and to form A2AR-A2BR
heteroreceptor complexes. Recently, ECV-mediated intercellular
communication in the CNS was classified as a component of VT
(Borroto-Escuela et al., 2015). The concept of ECV-mediated
VT was based on the highly significant work of Simons and
Raposo (Simons and Raposo, 2009), which demonstrated the
fundamental role of exosomes in intercellular communication.
However, it should be underlined that also alterations in
endogenous protein expression plays a major role in changing
the protein panorama in the cells.
It is proposed that such processes with increased formation
of A2AR-A2BR heteroreceptor complexes may represent an
important mechanism to counteract the neurodegenerative and
toxic effects in models of brain disease of the expression and
in vitro activation of A2ARs (as discussed above). Targeting
and increasing expression of A2AR-A2BR heteroreceptor
complexes via gene therapy involving the A2BR gene or
a pharmacological approach may be a novel strategy for
treatment of neurodegenerative disease in which A2AR over
activation and/or overexpression plays a detrimental role. The
pharmacological analysis can involve the identification of the
transcription factors activating the expression of the A2BR as
well as the use of a brain-penetrant heterobivalent compound
built up of an A2A receptor antagonist pharmacophor and an
A2BR agonist pharmacophor. Such a heterobivalent compound
may assist in the heteromerization process. The A2AR-A2BR
heteromer may be in balance with A2AR and A2BR homomers
and other types of A2AR and A2BR heteroreceptor complexes.
This homo and heteroreceptor panorama may vary among brain
regions and within glial-neuronal networks of the same region
and also among individual neurons and different types of glial
cells in the same region.
It should be mentioned that A2BRs can also counteract the
A1R produced inhibition of the glutamatergic transmission of
the hippocampus (Goncalves et al., 2015). It seems likely that
these findings reflect the existence of A1R-A2BR heteroreceptor
complexes in glutamate nerve terminals, where the two
adenosine receptor subtypes seem to be coexpressed.
ON THE ROLE OF A1R-A2AR
HETERORECEPTOR COMPLEXES
In line with the above proposal is the early demonstration
that A1R-A2AR heteromers exist in striatal and hippocampal
glutamate nerve terminals where A1R and A2AR receptors
were found to be colocalized (Rebola et al., 2005) and form
an isoreceptor complex in the rat brain (Figure 1). The major
receptor-receptor interaction found appears to be an A2AR
agonist produced reduction of A1R affinity. Therefore, at high
concentrations of adenosine, which can activate A2ARs, an
increase of glutamate release is found. In astrocytes a similar
mechanism maybe found involving A1R-A2AR heteromers
which via Gi/o and Gs proteins modulate GABA transport
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(Cristovao-Ferreira et al., 2011, 2013). It was proposed that the
structure might be based on heteromers formed from homomers
(Navarro et al., 2016b).
Taken together, it seems possible that with increased
concentrations of adenosine the allosteric receptor-receptor
interactions in the A1R-A2AR and putative A1R-A2BR
isoreceptor complexes will favor glutamate release which may
contribute to enhanced excitation and possible excitotoxicity.
ON THE EXISTENCE OF ADENOSINE
A2AR-RECEPTOR TYROSINE KINASE
HETERORECEPTOR COMPLEXES AND
THEIR ROLE IN NEUROPROTECTION
As clearly pointed out by Gomes et al. (2011), it is still not
clear if the trophic factors and their tyrosine kinase receptors
(RTK) play a significant role in the regulatory actions of
adenosine via A2AR activation, since these signals are supposed
to produce neuroprotection. A2AR receptor antagonists in
fact counteract neurodegeneration in a number of models.
Nevertheless, there is one interesting and significant publication
that demonstrates that activation of A2AR receptors can enhance
Trk neurotrophin receptor signaling which in this preparation
developed independently of neuroptrophins (Lee and Chao,
2001). Furthermore, in a beautiful paper FGF2 and A2AR
agonists were found to act via FGFR1 and A2AR to enhance
synaptic plasticity in the striatum (Flajolet et al., 2008). In this
case an FGFR1-A2AR heteroreceptor complex was demonstrated
(Flajolet et al., 2008; Borroto-Escuela et al., 2013a; Figure 2). It
seems likely that the results obtained in the Lee and Chao paper
(Lee and Chao, 2001) also reflects the existence of heteroreceptor
complexes between TrkA and A2AR and TrkB and A2AR in
which A2ARs enhance Trk signaling.
In line with these findings it was also found that chronic
in vivo treatment with an A2AR antagonist blocked the BDNF
induced facilitation of LTP. Thus, a reduction of BDNF action
was achieved (Jeronimo-Santos et al., 2014).
Based on the work presented in this article it appears
that treatment with A2AR antagonists and increased formation
of A2AR-A2BR heteroreceptor complexes should represent
novel strategies for alpha-synyclein induced neurodegeneration.
However, in the case of deficits in neurotransmission plasticity
A2AR agonists may be the way to go for treatment in view of
their ability to enhance TRK signaling.
FUNCTIONAL A2AR-GLUCOCORTICOID
RECEPTOR INTERACTIONS
It was recently demonstrated that A2ARs can induce a
dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis by
targeting the function of glucocorticoid receptors (GR; Batalha
et al., 2016). Overactivation of A2ARs leads to loss of plasma
glucocorticoid levels and reduction of hippocampal levels of
GR. The A2AR activation affected GR function by modulating
the transcriptional activity of GR and their nuclear location.
These are exciting findings and show that the A2AR is a major
modulator of the function of GR. It can represent one important
mechanism for the cognitive enhancement with improvement of
memory produced by A2AR antagonists (Batalha et al., 2016).
In our opinion a direct interaction of the membrane
located A2ARs with cytosolic-perimembrane GR should also be
considered. Glucocorticoid receptors also exist at the neuronal
membrane and can regulate nongenomic corticosteroid signaling
(Groeneweg et al., 2012). Thus, a direct receptor-receptor
interaction between the intracellular domains of the A2AR and
GR becomes possible. Through the formation of this complex the
A2AR can modulate the function of GR in two ways. The first
possibility is that the A2AR-GR complex became recruit to the
lysosome. As a results only the intracellular domains of the A2AR
may remain linked to the GR and be translocated to the nucleus
as a new component of GR. The link of these A2AR fragments
to the GR element can substantially alter the GR transcriptional
activity and represent a novel mechanism for modulation of gene
transcription. Another alternative is the A2AR is available to
recruit GR to the plasmamembrane to an increased extent. In this
way less GR will be available for translocation into the nucleus. In
this way the transcriptional activity of GR can become reduced,
instead the nongenomic GR signaling become dominant.
Interestingly, recent work demonstrated that the GR binds
to GREs in β-arrestin 1 and 2 and modulates their gene
expression (Oakley et al., 2012) which will became reduced by
the A2AR-GR heteroreceptor complex. Such mechanisms may
in fact have a major impact on the GR function leading to a
marked disturbance of synaptic plasticity andmemory. Thus, it is
proposed that such a A2AR-GR heteroreceptor complexmay lead
to a mechanism that can change the hippocampal transcription
panorama. The hippocampal connection to the hypothalamus
may also be affected leading to hypothalamic-pituitary-adrenal
dysfunction. Future work will establish if this hypothesis is of
value.
We have previously introduced the theory that long-term
memory becomes possible by the translocation of parts of the
heteroreceptor complexes into the nucleus over the perinuclear
membrane and promote the activation capability of a particular
set of transcription factors (Fuxe et al., 2014a,b; Borroto-
Escuela et al., 2015). These may then induce the transcription
of unique adaptor proteins that upon expression can bind to
the heteroreceptor complexes in the cytoplasmic component of
the plasma membrane and link them to the cytoskeleton and
major scaffolding proteins (Fuxe et al., 2014b). In this way they
become stabilized with conserved allosteric receptor-receptor
interactions.
A3R HETERORECEPTOR RECEPTOR
COMPLEXES
It should be noted that also adenosine A3Rs take part in
heteroreceptor complexes. So far A1R-A3R complexes have been
demonstrated in the cerebral cortex and dorsal hippocampus
(Hill et al., 2014) and A2AR-A3R isoreceptor complexes in the
dorsal hippocampus mainly in the pyramidal cell layer using
proximity ligation assay (Borroto-Escuela et al., 2016a; Figure 1).
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The function of complexes including A3R has not yet been
clarified.
CONCLUSIONS
The exciting work performed on A2AR mediated
neurodegeneration performed by several groups (Gomes
et al., 2011; Santiago et al., 2014; Laurent et al., 2016; Ferreira
et al., 2017a) opens up a major role for A2AR antagonists
in neurodegenerative disease involving alpha-synucleins. In
this perspective article we have proposed that adenosine
A2AR iso- and heteroreceptor complexes and their allosteric
receptor-receptor interactions can be key players in balance
with corresponding homorecepor complexes. In future work
it will therefore be crucial to characterize the heteroreceptor
complexes with FRET/BRET and proximity ligation assay and
their allosteric receptor-receptor interactions with radioligand
binding assays and their signaling pathways with luciferase
reporter gene assays. The receptor interface is usually different
between a receptor heteromer and the corresponding homomers.
Therefore, it becomes possible to selectively interfere with
formation of a receptor heteromer and thus its function vs.
corresponding homomers through use of interface interacting
peptides (Borroto-Escuela et al., 2010b, 2018).
Also a scheme was introduced how alpha-synuclein
monomers/oligomers/ synuclein fibrils can modulate the
adenosine A2AR homo-heteroreceptor panorama in the
plasma membrane through intramembrane and intracellular
interactions enhancing neurodegeneration (Figure 2). They
can exist both in neurons, astroglia and microglia. The role of
putative A2AR-D2R-NMDAR and A2AR-mGluR5-NMDAR
heteroreceptor complexes were inter alia discussed in relation
to glutamate synapses and excitotoxicity. Future work is
necessary to test the impact of these adenosine A2AR-containing
complexes on A2AR mediated neurodegeneration, especially
when mediated by alpha-synucleins.
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